Tufts CSDD Team
Tufts CSDD Faculty
Kenneth A. Getz, MBA
Executive Director and Research Professor
Ken Getz is the Executive Director of the Tufts Center for the Study of Drug Development and a Research Professor at the Tufts University School of Medicine. He is an internationally recognized expert on pharmaceutical R&D management and execution, protocol design, contract service provider and investigative site management, eClinical technology and data usage, and patient engagement. A well-known speaker at conferences, symposia, universities, investor meetings, and corporations, Ken has published extensively in peer-review journals, books, and in the trade press. He holds a number of board appointments in the private and public sectors. He received his MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and his bachelor’s degree from Brandeis University. Ken is also the chairman of CISCRP — a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise — and the founder of CenterWatch, a leading publisher in the clinical trials industry and one of several businesses that he has sold.
KEN’S CURRENT AND RECENT RESEARCH INITIATIVES INCLUDE:
Quantifying clinical trial participant diversity and disparities
Benchmarking protocol design practices and their impact on performance
Examining remote and virtual drug development activity and its effectiveness
Evaluating the adoption and value proposition/ROI of innovative practices and solutions
Measuring the impact of regulatory reforms on the cost and efficiency of drug development
Examining clinical data and real-world data management practices
Monitoring structural and operating changes in the global investigative site landscape
Assessing the evolving role of outsourcing and contract services in drug development
Joseph A. DiMasi, PhD
Director of Economic Analysis and Research Associate Professor
Dr. Joseph DiMasi is an internationally recognized expert on the economics of the pharmaceutical industry. He serves on the editorial board of Therapeutic Innovation and Regulatory Science and has previously served on the editorial boards of the Drug Information Journal, the Journal of Research in Pharmaceutical Economics, and the Journal of Pharmaceutical Finance, Economics & Policy. He has published in a wide variety of economic, medical, and scientific journals and has presented his research at numerous professional and industry conferences. Dr. DiMasi testified before the U.S. Congress in hearings leading up to the FDA Modernization Act of 1997 and reauthorization of the Prescription Drug User Fee Act. He received the Donald E. Francke Award from the Drug Information Association for the best article in the Drug Information Journal published in 2000. Dr. DiMasi received his doctorate in economics from Boston College in 1984.
Dr. DiMasi’s research interests include the R&D cost of new drug development, clinical success and phase attrition rates, development and regulatory approval times, R&D efficiency, the role that pharmacoeconomic evaluations have played in the R&D process, pricing and profitability in the pharmaceutical industry, innovation incentives for pharmaceutical R&D, and changes in the structure and performance of the pharmaceutical and biotechnology industries.
Mary Jo Lamberti, PhD
Director of Sponsored Research, Research Associate Professor
Dr. Mary Jo Lamberti is a Research Associate Professor at Tufts University School of Medicine and the Director of Sponsored Research at Tufts CSDD. She is an internationally recognized expert on benchmarking drug development operating practices. Her research focuses on a variety of areas including outsourcing and partnerships, clinical supplies, investigative site initiation and management, patient recruitment and retention, and the use of technologies and digital solutions in clinical trials. She has published extensively and is a frequent speaker at global conferences. Dr. Lamberti holds a BA from Wellesley College and a PhD in psychology from Boston University.
Dr. Lamberti’s Current Initiatives Include:
Study volunteer diversity in clinical trials
Machine learning and artificial intelligence (AI) in clinical research
Benchmarking patient recruitment and retention practices
Industry use of automation, IT technologies and applications
Jennifer Kim, PhD
Research Assistant Professor
Dr. Jennifer Kim is a Research Assistant Professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine. She is an organizational psychologist whose research and consulting focus on work and health equity. Specifically, she explores both system and individual-level barriers that contribute to disparities, while also examining macro and micro-level interventions that can help reduce barriers faced by historically marginalized communities. Recent projects have included quantifying the impact of workplace microaggressions among drug development professionals; exploring racial discrimination among patients in clinical trials; and understanding what inclusive leadership looks like in organizations. She received my BA from Wellesley College and Ph.D. in Organizational Psychology from Columbia University.
Dr. Kim's Current Initiatives Include:
- Workplace DEI dynamics and their impact on team performance
- Racial microaggressions experienced by patients in clinical trials
- The impact of socioeconomic status on perceptions of clinical trials
Kenneth I Kaitin, PhD
Professor and Senior Fellow
Kenneth Kaitin is Professor of Medicine at Tufts University School of Medicine and Senior Fellow at Tufts Center for the Study of Drug Development, where he previously served as Director for 23 years. He is also an Advisory Professor at Shanghai Medical College at Fudan University in China, and serves on the faculties of the European Center for Pharmaceutical Medicine at the University of Basel, the American Course on Drug Development and Regulatory Science at the University of California, San Francisco, and the IFAPP Academy-Kings College London Medical Affairs in Medicines Development Certification Program. Dr. Kaitin is internationally recognized for his contributions to the field of drug development policy and science. He consults, speaks, and writes on global trends in pharmaceutical development, and has provided public testimony before the U.S. Congress. A former President of the Drug Information Association, Dr. Kaitin served as Editor-in-Chief of Expert Review of Clinical Pharmacology, and as a consultant to the U.S. Department of Defense on bioterror countermeasures. In 2011 he received the Dr. Louis M. Sherwood Award, granted by the Academy of Pharmaceutical Physicians and Investigators; in 2020, he was named Global Fellow in Medicines Development by the International Federation of Pharmaceutical Physicians in 2020; and in 2021, he received the Distinguished Achievement Award from the Sino-American Pharmaceutical Professionals Association (SAPA). Dr. Kaitin is a director on the boards of Curis, Inc. (NASDAQ: CRIS), Bio-Tree Systems, Inc., and QCDx LLC. He earned his BS from Cornell University and MS and PhD in pharmacology from the University of Rochester.
Richard I. Shader, MD
Medical Consultant and Professor Emeritus
Dr. Richard Shader is Professor Emeritus of Immunology and Professor Emeritus of Psychiatry at the Tufts University School of Medicine in Boston, Massachusetts. Prior to joining the Tufts faculty, he was on the faculty at Harvard Medical School where he achieved the rank of Associate Professor. He is a former chairman of both the Department of Pharmacology and Experimental Therapeutics and the Department of Psychiatry at Tufts. Dr. Shader also served as Program Director for graduate studies in the program in Pharmacology & Experimental Therapeutics at the Sackler School of Biomedical Sciences. Currently, he is a Senior Research Fellow and Medical Consultant at the Tufts Center for the Study of Drug Development. In addition to being a former MERIT Investigator of the National Institutes of Health (NIH), Dr. Shader was also a member of the National Advisory Mental Health Council appointed by President Ronald Reagan. He has served on a NIMH study section and was a frequent ad hoc reviewer. He was a member of the Scientific Advisory Board for the NIMH Hypericum Trial and of the Advisory Board for the NIMH Research Units in Pediatric Psychopharmacology. He served on the overall Data Safety Monitoring Board (DSMB) for the NIH Center for Complementary and Alternative Medicine as well as on the DSMB for its Silymarin trials. He currently chairs the DSMB for COMPASS Pathway’s Psilocybin for Depression trial. Dr. Shader was the President of the American College of Neuropsychopharmacology (ACNP), the American Board of Psychiatry and Neurology (ABPN), and the American Association of Chairmen of Departments of Psychiatry (AACDP). He is a former director and member of the Executive Committee of the American Board of Emergency Medicine (ABEM) and still serves as a senior director. Dr. Shader was an individual winner of the American Psychiatric Association’s Seymour Vestermark Award for Psychiatric Education. He received this award a second time with colleagues from the ACNP. He has been a member of the Scientific Advisory Board of the Alzheimer’s Foundation and the Association for Aging Research. During the academic year 1990–1991, he was the Kaiser Family Fellow at the Center for Advanced Studies in the Behavioral Sciences in Stanford, California. A 1956 graduate of Harvard College, Dr. Shader received his medical degree from the New York University School of Medicine in 1960. He received his psychiatric training at the Massachusetts Mental Health Center at Harvard Medical School and at the NIMH in Bethesda, Maryland. He graduated from the Boston Psychoanalytic Institute where he was a Joseph Michels merit scholar. He was the founding Editor-in-Chief (E-i-C) of the internationally known journal, the Journal of Clinical Psychopharmacology (1980–2020) and was also the E-i-C of the international journal Clinical Therapeutics (2012–2019). He is now E-i-C Emeritus for both journals. In addition, he is the author or co-author of over 1,000 scientific publications and the author, editor, or co-editor of 21 scientific books and monographs. According to ResearchGate, as of January 2021 his publications have received over 26,250 citations in peer-reviewed journals; and his h-index is 86. According to Google Scholar, his h-index is 101. This includes book chapters.
Robert Franco, PhD
Senior Fellow Tufts CSDD and President, Coe Point Associates LLC
With over 24 years of consulting experience, Dr. Franco led PricewaterhouseCoopers’ Pharmaceutical R&D practice where he specialized in improving pharmaceutical drug development, technology transfer, clinical trial operations and manufacturing. The breadth of his career includes having worked with the senior management of several large pharmaceutical and biotechnology companies, Non-government Organizations (NGOs) and multinational organizations to implement complex change management initiatives to improve growth, reduce costs and remediate quality and regulatory issues. In addition to Dr. Franco’s writing which includes eight management consulting articles and thirteen technical publications, he has three patents to his name and has served on several international technical review and regulatory standards committees. Dr. Franco holds a Doctor of Philosophy and Master of Science in Biochemistry from the University of Rochester.
Paul Beninger, MD, MBA
Adjunct Research Professor
Dr. Beninger is an adjunct research professor at Tufts CSDD and an Associate Professor of Public Health & Community Medicine at Tufts University School of Medicine. He has more than three decades of career experience as a regulator, industry executive, and as a member of the academic community. Dr Beninger began his career in drug development in 1987 at the US Food and Drug Administration, first as a reviewer and manager for drugs against HIV/AIDS and opportunistic infections and then as a division director for medical devices. He joined Merck & Company in 1995 in regulatory affairs, medical affairs and drug safety in the areas of anti-infective drug and biological products, vaccines, anti-diabetic drug products and oncology drug products, before joining Genzyme as vice-president of pharmacovigilance in 2006. Dr. Beninger trained in internal medicine and infectious diseases. He received his MD from the University of California, Davis, his BA from Claremont McKenna College in Claremont, California, his MBA from St Joseph’s University in Philadelphia, Pennsylvania, and his graduate certificate in epidemiology from Tufts. He consults regularly and has published and presented his research and insights extensively. Dr. Beninger has been affiliated with Tufts Center for the Study of Drug Development since 2014 and Tufts Clinical and Translational Science Institute since 2021.
Ronald P. Evens, B.S. Pharm., Pharm.D., FCCP
Adjunct Research Professor and Biotechnology Industry Consultant
Dr. Evens is an internationally recognized expert on the biotechnology industry, a market that he has studied for more than 30 years. He has extensive experience in both academia and in industry. He was an adjunct professor of pharmacy at University of Florida and the University of Pacific; an Associate Professor & Chairman, Department of Pharmacy Practice, University of Tennessee; and Associate Professor & Director of the Drug Information Center at the University of Texas at Austin. Dr. Evens was also a Senior Director of the Professional Services Department at Amgen; and an Associate Director, Clinical Research & Medical Services at Bristol-Myers Company. He is the editor and author of four books; has authored over 100 publications; given more than 150 professional and industry presentations; and serves on a variety of non-profit and for-profit boards. Dr. Evens is also the president of M.A.P.S. 4 Biotec, Inc, a consulting firm that he founded focusing on the biotechnology industry for medical affairs. Dr. Evens received a B.S. in Pharmacy from the University of Buffalo and received his Pharm. D. From the University of Kentucky.
Dr. Chandresh Harjivan, PharmD, MPH, MBA
Senior Fellow, Tufts CSDD
Dr. Harjivan is a recognized international expert on strategy and operations, change management and workforce development in biopharmaceutical R&D and health care environments within private and public sectors. With more than 20 years of experience as a partner, managing director and consultant at a number of firms (including the Boston Consulting Group, PWC and PRTM), Dr. Harjivan works closely with Dr. Franco on Tufts CSDD’s Core Strategic Visioning Assessments. Dr. Harjivan holds a PharmD from the University of Maryland, an MPH from Johns Hopkins University and an MBA from Oxford University.
Zeid Barakat, MBA
Senior Fellow, Tufts CSDD
Zeid Barakat is a Managing Director at Scimitar Inc. and was a Director at PwC. He has led major R&D transformations, focusing on Clinical and Tech Ops initiatives, large-scale CRO/ CMO partnerships, post-merger integrations, new product launches, operational turnarounds and digital platform rollouts. Mr. Barakat is a lecturer in Tufts CSDD’s professional development courses, a co-facilitator at CSDD roundtables and a consultant on projects with Ken Getz and other members of the CSDD team. He earned his MBA from the MIT Sloan School of Management, a Masters in Biotechnology from Harvard, and a BA from Bowdoin College.
Linda B. Sullivan, MBA
Senior Fellow, Tufts CSDD
Ms Sullivan has more than 30 years of experience, in health care and in clinical research, helping organizations optimize processes to improve financial and quality outcomes. She is the founder and served as the Executive Director of the Metrics Champion Consortium, a cross-industry collaboration dedicated to developing standardized performance metrics for sponsors, CROs and investigative sites to oversee and manage studies, identify improvement areas and assess process improvement opportunities. A well known speaker at performance metrics, Quality by Design, risk based quality management and clinical trial oversight meetings, Linda has published extensively in leading journals, hosted the Clinical Trial Optimization Podcast Show, and served on industry advisory boards including the NIH-NCATS Methods and Process Domain Task Force. Ms Sullivan received her BS in Biology from Trinity College and her MBA from the Amos Tuck School of Business at Dartmouth where she was named a Tuck Scholar.
Tufts CSDD Research Staff
Zachary (Zak) Smith, MA
Project Manager and Data Scientist
Zak Smith works on a variety of Tufts CSDD studies focusing on drug development performance, efficiency, economics and innovation adoption. Many of these projects involve creating, compiling, and analyzing very large datasets. Zak completed his BS at Florida Southern College and received his MA from Brandeis University. He is a former research analyst at Tufts CSDD and has worked as a research assistant at Harvard University and at the University of Massachusetts.
Maria I. Florez, MA
Senior Analyst and Research Consultant
Maria Florez is involved with projects conducted by the Tufts CSDD Sponsored Research Group, including studies looking at the impact of digital transformation in clinical research and at organizational strategies and practices driving improvement in development operations and economics. Maria has been a researcher and strategist in the healthcare sector for more than a decade. She has held positions at Cleveland Clinic and at New York-Presbyterian Hospital of Columbia and Cornell Universities. Maria holds a bachelor’s degree with honors in economics from Stony Brook University and a master’s degree from The Fletcher School of Law and Diplomacy at Tufts University.
Beth Harper, MBA
Project Manager and Senior Research Consultant
Beth Harper works closely with Tufts CSDD Director Ken Getz and the Sponsored Research Group on a variety of projects, including studies on: drug development execution; sponsor-site relationship management; study feasibility and start-up; investigative site selection; patient recruitment and retention; workforce effectiveness and competency; and the adoption and impact of operating and data management innovations. Beth is the president of Clinical Performance Partners, Inc., and is also an Adjunct Assistant Professor at George Washington University. She has published and presented extensively. Beth received her BS in Occupational Therapy from the University of Wisconsin and her MBA from the University of Texas.
Patricia (Trish) Davidson, MPA
Senior Consultant and Project Manager
Trish Davidson has extensive experience -- most recently developing an international Biomarkers and Outcome Measures Consortium for a rare disease patient advocacy group and 13+ years at the Lupus Foundation of America -- developing and directing patient and professional educational programs, research symposia and consortia involving diverse stakeholder communities in clinical care and clinical research. Trish collaborates with Tufts CSDD Executive Director Ken Getz on a variety of initiatives involving building and sustaining relationships with professionals in government, advocacy, academia and industry. Trish received her BA and Masters of Public Administration (MPA) from the University of South Carolina.
Emily Botto, BA
Senior Research Analyst
Emily Botto is involved with projects in the Sponsored Research Group where she works on a variety of studies focusing on clinical research execution strategies and practices as well as clinical trial diversity and inclusion. Emily brings experience as a managing and contributing editor for a newspaper and book publishing company. She also worked as a market research analyst with the VDC Research Group. Emily graduated from Brandeis University with BAs in Business and Communication.
Abigail Dirks, MS
Research Data Analyst
Abigail Dirks is a Research Data Analyst at the Center where she assists in preparing and analyzing large and complex data sets based on primary and secondary research studies. Abigail recently received her MS in the Health Informatics and Analytics program at Tufts University and received her BS in Data Science and Mathematics from St. Michael’s College. She also has experience as a Web Developer for North Shore Nurse Practitioner Associates.
Madison Ford, MPH
Madison Ford is a Research Analyst at the Center where she conducts grant-funded research including survey and database design, quantitative and qualitative data analysis, and literature reviews. In 2021, Madison received her BS in Public Health from The University of Alabama. She recently received her MPH in Health Management and Policy from Georgia State University. Madison has experience in various health organizations including the Georgia Health Policy Center, Georgia Early Education Alliance for Ready Students, and Planned Parenthood.
Hana Do, BS
Hana Do is a Research Analyst at Tufts CSDD where she conducts grant-funded research including interviews, quantitative and qualitative data analysis, and literature reviews. Hana received her BS in Health Science from Boston University in 2021. She recently received her MPH in Epidemiology and Biostatistics from Boston University School of Public Health. Hana has experience in data management and data analysis using SAS with Boston Medical Center’s Cancer Prevention Research Study.
Sarah Wrobel, MHA
Ava Feuer, B.S.
Lindsey Perreault, MPH
Associate Director of CFR
Lindsey Perreault joined the Tufts Corporate and Foundation Relations team in October 2021. As an Associate Director of CFR, Lindsey provides support to the CSDD by managing its Circle of Supporter members and assisting with fundraising efforts. Prior to joining Tufts, Lindsey was a Partnerships and Development Manager at Last Mile Health, where she secured funding for community health programs across Sub-Saharan Africa. Before Last Mile Health, she supported fundraising and communications efforts at The Children’s Inn at NIH. Lindsey received her MPH from George Washington University and her B.S. in Health Science from Boston University.
Ronald W. Hansen, Ph.D.
We are saddened to report that respected colleague and friend, Dr. Ronald W. Hansen, passed away on July 5, 2023. Dr. Hansen had a long and productive association with CSDD. Dr. Hansen received his Ph.D. in economics from the University of Chicago. He retired from the University of Rochester, where he was Senior Associate Dean for Faculty & Research in the Simon School of Business. Dr. Hansen was Associate Director of the Center for Research in Government Policy and Business at the University of Rochester at the time that CSDD was formed at the University. He briefly left the University of Rochester in the late 1980s to become the first recipient of the Merrill Dow Professorship of Pharmaceutical Administration in the College of Pharmacy at the Ohio State University. Dr. Hansen was a consultant with CSDD at its inception and for many years after that. He collaborated with CSDD scholars on research, most importantly as an author on a series of papers on the cost of new drug development that continue to impact policy makers, regulators, pharmaceutical developers, and academics worldwide. Dr. Hansen helped establish CSDD as an influential force in pharmaceutical development and regulation. Ron will be greatly missed as a friend and colleague.